“
“Purpose: To investigate the gene polymorphism of CYP2D6*10 (C188T) in the Hui people and study its correlation between CYP2D6*10 gene mutation and structure and function of its encoding protein.
Methods: 150 unrelated Hui ethnic group volunteers participated in this study. A total of 500 mu L heparin-treated blood from each volunteer was extracted with the TIANGEN DNA Mini
Kit. Allele specific amplification PCR and Gene sequencing were used to detect the CYP2D6 alleles *10. Bioinformatics and computer modeling methods were used to predict the spatial structure and function of the protein encoded by the wild type gene and mutant gene.
Results: The mutation frequency of C188T allele (T) of CYP2D6*10 in Ningxia Hui people was 47.5 %, compared with Turkish (14.5 %), Ethiopia (8.6 %), Spanish (1.9 %), and they were significantly different, (p < 0.01;) The result from ProtParam shows that mutant protein was more unstable GDC-0973 concentration than the wild-type protein. The isoelectric point, molecular weight and hydrophilicity were similar in terms of mutant protein and wild-type protein. Analysis of the gene sequence of CYP2D6*10 using DNAStar/Protein software indicates that the mutant protein had one more Gamier-Robson Turn while MotifScan analysis showed that the wild-type protein had 2 P450 enzyme
activation sites and that there was none in the mutant protein. Analysis using SignalP demonstrated that the wild-type protein had signal peptide while the mutant protein had none. Analysis using TMHMM Server showed that both of them had a selleck inhibitor CA3 nmr transmembrane region. The foregoing differences between the mutant protein and the wild-type protein could influence the activity of CYP2D6.
Conclusion: Gene mutation can change the spatial structure and function of CYP2D6.
This change may be the main reason for the decreased activity of the enzyme.”
“Purpose of review
Systemic sclerosis is commonly complicated by pulmonary arterial hypertension (PAH-SSc) and is a leading cause of death in this population. We will review existing challenges and recent advances in the treatment of this disease.
Recent findings
Traditionally employed outcome measures in pulmonary arterial hypertension research may not be applicable in PAH-SSc. Importantly, new therapies that target abnormal cellular proliferation in the pulmonary vasculature are currently under investigation and may be particularly relevant to PAH-SSc.
Summary
Pulmonary arterial hypertension complicating systemic sclerosis occurs commonly and portends a poor prognosis. However, recent advances in our understanding of the disease in the context of systemic sclerosis may lead to novel diagnostic and therapeutic strategies that will ultimately improve quality of life and survival in this population.”
“Objective: alpha 1-Antitrypsin (AAT) is protective of tissue damage induced by enzymes of inflammatory cell source.